IMAB Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

18 days ago - By: I-Mab Biopharma

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

24 days ago - By: I-Mab Biopharma

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

3 months ago - By: Everest Medicines

Everest Medicines Expands Strategic Investment in I-MAB

a month ago - By: I-Mab Biopharma

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

a month ago - By: Benzinga - Mentions: PDEX NDRA SRRK ADTX ...

12 Health Care Stocks Moving In Monday's Intraday Session

a month ago - By: Benzinga - Mentions: IVA YCBD IMTX NBTX ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Zacks Investment Research

I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know

2 months ago - By: I-Mab Biopharma

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

2 months ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice

3 months ago - By: I-Mab Biopharma

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

3 months ago - By: I-Mab Biopharma

I-Mab to Participate in September Investor Conferences

3 months ago - By: I-Mab Biopharma

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: I-Mab Biopharma

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

4 months ago - By: I-Mab Biopharma

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

4 months ago - By: I-Mab Biopharma

I-MAB-SPONSORED ADR (IMAB) Stock News

IMAB Latest News, Press Relases and Analysis

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

Everest Medicines Expands Strategic Investment in I-MAB

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Friday's After-Market Session

I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

I-Mab to Participate in September Investor Conferences

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

I-Mab to Present at the BTIG Virtual Biotechnology Conference